Can IVIM help predict HCC recurrence after hepatectomy?

AbstractPurposeTo determine the diagnostic performance of intravoxel incoherent motion (IVIM) parameters to predict tumor recurrence after hepatectomy in patients with hepatitis B virus (HBV) –related hepatocellular carcinoma (HCC).Materials and methodsOne hundred and fifty-seven patients (mean age 52.54  ± 11.32 years, 87% male) with surgically and pathologically confirmed HCC were included. Regions of interests were drawn including the tumors by two independent radiologists. ADC and IVIM-derived parameters (true diffusion coefficient [D]; pseudodiffusion coefficient [D*]; pseudodiffusion fraction [f]) were obtained preoperatively. The Cox proportional hazards model was used to analyze the predictors associated with tumor recurrence after hepatectomy.ResultsForty-seven of 157 (29.9%) patients experienced tumor recurrence. The multivariate Cox proportional hazards model revealed that aD value
Source: European Radiology - Category: Radiology Source Type: research

Related Links:

ino Worldwide, approximately 10% of all human immunodeficiency virus (HIV)-infected people are also chronically coinfected with hepatitis B virus (HBV). HBV infection has a poor prognosis in HIV-positive people and has been documented by an increased risk of developing chronic HBV infection (CHB), progression to liver fibrosis and end-stage liver disease (ESLD) and evolution of hepatocellular carcinoma (HCC). Furthermore, in HIV patients, HBV-resolved infection is often associated with the appearance of HBV-DNA, which configures occult HBV infection (OBI) as a condition to be explored in coinfected patients. In this na...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
This study aimed to discover a diagnostic or a screening biomarker from the urine of HBV-related HCC patients. We used iTRAQ coupled with mass spectrometry to identify candidate urinary proteins in a discovery cohort (n=40). The selected proteins were confirmed using ELISA in a validation cohort (n=140). Diagnostic performance of the selected proteins was assessed using receiver operating characteristic (ROC) and qualitative diagnostic analysis. A total of 96 differentially expressed proteins were identified. Urinary alpha-fetoprotein (u-AFP) and orosomucoid 1 (u-ORM1) were selected as target proteins by bioinformatics ana...
Source: Am J Physiol Gastroi... - Category: Gastroenterology Authors: Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research
We present a narrative review of HCC in Africa, discussing present and future trends. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Seminars in Liver Disease - Category: Gastroenterology Authors: Tags: Review Article Source Type: research
Conditions:   Hepatitis B, Chronic;   Hepatocellular Carcinoma;   Compensated Cirrhosis Interventions:   Drug: Entecavir;   Drug: Tenofovir Disoproxil Sponsors:   Qing XIe;   Shanghai MedSci Healthcare Co. Ltd Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackground and AimsThe features of non-viral, nonalcohol hepatocellular carcinoma (NBNC-HCC) remain elusive. The aim of this study was to investigate this clinical characteristics and overall survival of NBNC-HCC compared to hepatitis B- (HBV-HCC) and hepatitis C-related (HCV-HCC) HCC.MethodsWe analyzed the etiologies, fibrosis stages, clinical data, and outcomes of newly diagnosed patients with HCC.ResultsA total of 1777 HCC patients were recruited, including 332 patients with NBNC-HCC, 682 patients with HBV-HCC, 680 patients with HCV-HCC, and 83 patients with HBV/HCV HCC. Patients with NBNC-HCC were older (69.9 &...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
We read with great interest the article, ‘A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea’ by Kim et al., published in the Journal of Hepatology.1 The authors concluded that the risk of hepatocellular carcinoma (HCC) and death or orthotopic liver transplant w as no different between entecavir (ETV) and tenofovir (TDF) groups. Their findings were not consistent with the results of a study by Choi et al.2
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
In conclusion, PD-1+ TIGIT+ CD8+ T-cell populations are associated with accelerated disease progression and poor outcomes in HBV-HCC, which might not only have important clinical implications for prognosis but also provide a rationale for new targets in immunotherapy.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Conclusions: The results obtained from these 5 cases demonstrate impressive tumor control from the combination of SBRT and checkpoint inhibitors in patients with large tumors of advanced HCC. Further prospective trials are warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Semin Liver Dis DOI: 10.1055/s-0039-3399561Over 38,000 cases of hepatocellular carcinoma (HCC) are estimated to occur in Latin America annually. The region is characterized by sociocultural heterogeneity and economic disparities, which impose barriers in addressing this major health issue. A significant proportion of patients are still diagnosed in the later stages of the disease, although efforts to implement effective screening programs have been reported by referral centers. While viral hepatitis remains the predominant etiology of liver disease among HCC cases in Latin America, a high prevalence of fatty liver disease ...
Source: Seminars in Liver Disease - Category: Gastroenterology Authors: Tags: Review Article Source Type: research
First of all, we greatly appreciate the letter from Yu et al.,1 which addressed several concerns regarding our study2 where we concluded that the risk of hepatocellular carcinoma (HCC) was not statistically different between patients treated with entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF) for chronic hepatitis B virus (HBV) infection. Actually, the controversy concerning which antiviral agent is better in improving prognosis among patients with chronic HBV infection remains, however, the level of evidence favoring the use of any specific antiviral agent has been weak.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer | Radiology